{
const t = d3.range(0, 181, 5);
const glu = t.map(m => ({ t: m, y: 90 + 70 * (m / 45) * Math.exp(1 - m / 45) }));
const ins = (scale) => t.map(m => 6 + scale * 50 * (m / 50) * Math.exp(1 - m / 50));
const iv = ins(0.4), oral = ins(1.0);
const insData = t.flatMap((m, i) => [
{ t: m, y: oral[i], route: "Oral glucose" },
{ t: m, y: iv[i], route: "IV glucose (isoglycemic)" }
]);
const area = t.map((m, i) => ({ t: m, y1: iv[i], y2: oral[i] }));
const common = { width: 330, height: 260, x: { label: "Time (min)" }, marginLeft: 50 };
return html`<div style="display:flex;flex-wrap:wrap;gap:1rem;justify-content:center">
${Plot.plot({ ...common, y: { label: "Blood glucose (mg/dL)", domain: [60, 180] },
marks: [Plot.line(glu, { x: "t", y: "y", stroke: "#888", strokeWidth: 3 }),
Plot.text([{ t: 120, y: 165 }], { x: "t", y: "y", text: () => "Oral = IV" })] })}
${Plot.plot({ ...common, y: { label: "Insulin (μU/mL, relative)", domain: [0, 65] },
color: { legend: true, range: ["#d6604d", "#4393c3"] },
marks: [Plot.areaY(area, { x: "t", y1: "y1", y2: "y2", fill: "#d6604d", fillOpacity: 0.15 }),
Plot.line(insData, { x: "t", y: "y", stroke: "route", strokeWidth: 3 }),
Plot.text([{ t: 100, y: 42 }], { x: "t", y: "y", text: () => "Incretin effect" })] })}
</div>`;
}1 What Is the Incretin Effect?
1.1 Same blood glucose, different insulin response
In the 1960s, the following experiment was performed (Elrick 1964; McIntyre 1964).
- Subjects drank glucose (oral glucose load)
- On another day, glucose was infused intravenously so as to produce exactly the same blood glucose profile as in 1. (isoglycemic IV glucose)
Although the blood glucose profiles were the same, insulin secretion was much greater when glucose was given orally.
What creates this difference are hormones secreted as glucose passes through the gut —— the incretins (incretin: INtestine seCRETion INsulin).
In healthy people, an estimated 50–70% of postprandial insulin secretion is due to the incretin effect (Nauck 1986).
ImportantKey point
Incretin effect = the difference between “the insulin response to oral glucose” and “the insulin response when the same glucose profile is reproduced intravenously”.
1.2 Two hormones take the lead
Two hormones are currently established as having incretin action.
| GIP | GLP-1 | |
|---|---|---|
| Discovery | 1970s (as a substance that suppresses gastric acid secretion) | 1980s (from analysis of the proglucagon gene) |
| Secreting cell | K-cells | L-cells |
| Main site of secretion | Duodenum, upper jejunum (upstream in the gut) | Ileum, colon (downstream in the gut) *also present in the upper small intestine |
| Number of amino acids | 42 | 30–31 (active forms) |
| Contribution to the incretin effect in healthy people | Large (the main player) | Smaller than GIP |
GIP was first named gastric inhibitory polypeptide. It was later found that its main physiological action in humans is the stimulation of insulin secretion, so the abbreviation GIP was kept and reinterpreted as glucose-dependent insulinotropic polypeptide.
1.3 The incretin effect is reduced in type 2 diabetes
In patients with type 2 diabetes, the incretin effect is greatly reduced (Nauck 1986). The important points regarding the cause are:
- GIP secretion is largely preserved, but the β-cell response to GIP is greatly reduced
- The response to GLP-1 is relatively preserved, and insulin secretion recovers when pharmacological doses of GLP-1 are given
This observation — “GIP doesn’t work, but GLP-1 does” — first steered research toward making GLP-1 into a drug (Chapter 6). GIP was re-evaluated about 20 years later.
flowchart LR
A["Type 2 diabetes:<br/>incretin effect↓"] --> B{"Which<br/>hormone is the problem?"}
B --> C["GIP: it is secreted<br/>but β-cells don't respond"]
B --> D["GLP-1: at pharmacological doses<br/>β-cells still respond"]
D --> E["Let's make GLP-1 a drug<br/>(2005– GLP-1RA)"]
C --> F["GIP can't be a drug?<br/>→ re-evaluated in the 2010s<br/>(Chapter 6)"]
1.4 Summary
- Oral glucose elicits more insulin secretion than intravenous glucose (the incretin effect)
- The players are GIP (K-cells, upper small intestine) and GLP-1 (L-cells, lower small intestine)
- The incretin effect is reduced in type 2 diabetes. In particular, the response to GIP is reduced, while the response to GLP-1 is relatively preserved